世界の遺伝子検査市場動向...市場調査レポートについてご紹介

1. Analyst View
2. Research Methodology
3. Genetic Testing Overview
3.1 Application and Advantages
3.2 Methods
4. Global Genetic Testing Market Overview
4.1 Market Outlook
4.2 Genetic Testing Laboratories – Unmet Need Analysis
4.3 Direct-to-Consumer (DTC) Genetic Testing
5. Drivers & Challenges
5.1 Drivers
5.1.1 Increasing Public Awareness for Genetic Tests
5.1.2 Rising Incidence of Chronic Diseases
5.1.3 Growth in Ageing Population
5.2 Challenges
5.2.1 Decline in Fertility Rates
5.2.2 Ethical and Policy Issues
6. Disease-Wise Analysis
6.1 Alzheimer’s Disease
6.2 Cystic Fibrosis
6.3 Cancer
6.4 Bloom Syndrome
7. Country-Level Analysis
7.1 US
7.1.1 Market Overview
7.1.2 Recent Developments
7.2 Europe
7.2.1 Market Overview
7.2.2 Recent Developments
7.3 Asia-Pacific
7.3.1 Market Overview
7.3.2 Recent Developments
8. Emerging Sectors
8.1 Next-Generation Sequencing (NGS)
8.2 Non-Invasive Prenatal Testing (NIPT)
8.3 Whole Genome Sequencing (WGS) for Cancer
8.4 Personalized Medicine
9. Genetic Testing Regulation
10. Competitive Assessment
10.1 Abbott Laboratories
10.1.1 Company Overview
10.1.2 Product Offering
10.1.3 Key Financials
10.1.4 Recent Developments
10.1.5 Strengths & Weaknesses
10.2 Roche Diagnostics
10.2.1 Company Overview
10.2.2 Product Offering
10.2.3 Key Financials
10.2.4 Recent Developments
10.2.5 Strengths & Weaknesses
10.3 Myriad Genetics, Inc.
10.3.1 Company Overview
10.3.2 Product Offering
10.3.3 Key Financials
10.3.4 Recent Developments
10.3.5 Strengths & Weaknesses
10.4 Thermo Fisher Scientific
10.4.1 Company Overview
10.4.2 Product Offering
10.4.3 Key Financials
10.4.4 Recent Developments
10.4.5 Strengths & Weaknesses
10.5 Agilent Technologies Inc.
10.5.1 Company Overview
10.5.2 Product Offering
10.5.3 Key Financials
10.5.4 Recent Development
10.5.5 Strengths & Weaknesses
10.6 Hologic, Inc.
10.6.1 Company Overview
10.6.2 Product Offering
10.6.3 Key Financials
10.6.4 Recent Developments
10.6.5 Strengths & Weaknesses
10.7 Illumina, Inc.
10.7.1 Company Overview
10.7.2 Product Offering
10.7.3 Key Financials
10.7.4 Recent Developments
10.7.5 Strengths & Weaknesses
10.8 Qiagen NV
10.8.1 Company Overview
10.8.2 Product Offering
10.8.3 Key Financials
10.8.4 Recent Developments
10.8.5 Strengths and Weaknesses
10.9 Cepheid
10.9.1 Company Overview
10.9.2 Product Offering
10.9.3 Key Financials
10.9.4 Recent Developments
10.9.5 Strengths and Weaknesses
10.10 Affymetrix, Inc.
10.10.1 Company Overview
10.10.2 Product Offering
10.10.3 Key Financials
10.10.4 Recent Developments
10.10.5 Strength and Weaknesses

List of Figures:

Figure 4-1: Genetic Testing Market (Billion US$), 2014-2020
Figure 4-2: Genetic Testing Market by Geography (%), 2014
Figure 4-3: Genetic Testing Market by Geography (%), 2020
Figure 7-1: Number of Disorders, Genes, Labs, & Clinics for Genetic Testing (2014 & 2015)
Figure 7-2: Number of Genetic Tests Performed (2013-2015)
Figure 7-3: US – Genetic Testing Market (Billion US$), 2014-2020
Figure 7-4: Europe – Genetic Testing Market (Billion US$), 2014-2020
Figure 7-5: Asia-Pacific – Genetic Testing Market (Million US$), 2014-2020
Figure 8-1: Global – Next Generation Sequencing Market (Billion US$), 2014-2020
Figure 8-2: Global – NGS Application by Sector (%)
Figure 8-3: Global – Next Generation Sequencing Market by Player (%), 2013
Figure 8-4: Global – Non-Invasive Prenatal Testing Market (Million US$), 2014-2020
Figure 8-5: US – Tapped and Untapped Personalized Cancer WGS Market (%), 2013
Figure 8-6: US – Personalized Cancer WGS Market (Million US$), 2014-2020
Figure 8-7: Organizational Transformation to Support Personalized Medicine
Figure 9-1: Genetic Testing Regulatory Agencies
Figure 10-1: Abbott Laboratories – Revenue Breakup by Segments (%), 2014
Figure 10-2: Abbott Laboratories – Revenue Breakup by Geography (%), 2014
Figure 10-3: Roche Holding – Revenue Breakup by Segments (%), 2014
Figure 10-4: Roche Holding – Diagnostic Division Revenue by Geography (%), 2014
Figure 10-5: Myriad Genetics – Revenue Breakup by Segments (%), 2014
Figure 10-6: Life Technologies – Revenue Breakup by Segments (%), 2014
Figure 10-7: Life Technologies – Revenue Breakup by Geography (%), 2014
Figure 10-8: Agilent – Revenue Breakup by Segments (%), 2014
Figure 10-9: Hologic – Revenue Breakup by Segments (%), 2014
Figure 10-10: Hologic – Revenue Breakup by Geography (%), 2014
Figure 10-11: Illumina – Revenue Breakup by Geography (%), 2014
Figure 10-12: Qiagen NV – Revenue Break up by Segments (%), 2014
Figure 10-13: Qiagen NV – Revenue Break up by Geography (%), 2014
Figure 10-14: Cepheid – Revenue Break up by Segments (%), 2014
Figure 10-15: Cepheid – Revenue Break up by Geography (%), 2014
Figure 10-16: Affymetrix – Revenue Breakup by Segments (%), 2014
Figure 10-17: Affymetrix – Revenue Breakup by Geography (%), 2014

List of Tables:

Table 4-1: Key DTC Genetic Testing Companies by Category
Table 4-2: Key Test Areas Offered in DTC Genetic Testing Segment
Table 7-1: FDA Approved Pharmacogenomic Biomarkers for Oncology
Table 9-1: Abbott Laboratories – Key Gene Based Products
Table 9-2: Abbott Laboratories – Financial Performance (Million US$), 2012-2014
Table 9-3: Roche Molecular Diagnostics – Key Gene Based Products
Table 9-4: Roche Holding – Financial Performance (Million US$), 2012-2014
Table 9-5: Myriad Genetics – Key Gene Based Products
Table 9-6: Myriad Genetics – Financial Performance (Million US$), 2012-2014
Table 9-7: Life Technologies – Key Gene Based Products
Table 9-8: Life Technologies – Financial Performance (Million US$), 2012-2014
Table 9-9: Agilent – Key Gene Based Products
Table 9-10: Agilent – Financial Performance (Million US$), 2012-2014
Table 9-11: Hologic – Key Gene Based Products
Table 9-12: Hologic – Financial Performance (Million US$), 2012-2014
Table 9-13: Illumina – Key Gene Based Products
Table 9-14: Illumina – Financial Performance (Million US$), 2012-2014
Table 9-15: Qiagen NV – Key Gene Based Products
Table 9-16: Qiagen NV – Financial Performance (Million US$), 2012-2014
Table 9-17: Cepheid – Key Gene Based Products
Table 9-18: Cepheid – Financial Performance (Million US$), 2012-2014
Table 9-19: Affymetrix – Key Gene Based Products
Table 9-20: Affymetrix – Financial Performance (Million US$), 2012-2014